fbpx

X

Targeting Pressing Unmet Needs in Kidney Diseases with Unicycive Therapeutics CEO Dr. Shalabh Gupta — Episode 201

Targeting Pressing Unmet Needs in Kidney Diseases with Unicycive Therapeutics CEO Dr. Shalabh Gupta — Episode 201

In this episode, Ayesha spoke with Shalabh Gupta, MD, founder, chairman and CEO of Unicycive Therapeutics, a company focused on addressing unmet medical needs in renal diseases.

Kidney diseases are a major global health concern. In the US, chronic kidney disease (CKD) affects more than one in seven individuals, and one in three adults with diabetes may have the condition.

Before founding Unicycive Therapeutics in 2016, Dr. Gupta served in various roles, including founder and CEO of Biocycive, a commercial strategy role at Genentech and as an equity researcher at UBS Investment Bank and Rodman & Renshaw (currently HC Wainwright). Dr. Gupta is also the founder and CEO of Globavir, which licensed diagnostic technology from Stanford University and then partnered with global commercial diagnostic companies.

Dr. Gupta also serves as an advisor to the University of California San Francisco (UCSF) Innovation Center, a role he has held since 2020.

Before his roles in business and finance, Dr. Gupta was an attending physician at NYU Medical Center and a clinical faculty member at the NYU School of Medicine. Dr. Gupta received his MPA in Health Care Finance and Management from NYU’s Robert F. Wagner Graduate School of Public Service and his MD from Jawaharlal Institute of Postgraduate Medical Education & Research, India.

Tune in to discover how Unicycive Therapeutics is tackling the most pressing unmet needs in renal diseases and driving innovation in kidney health.
Listen on Apple Podcasts

The weekly podcast is available for streaming every Wednesday on SpotifyApple Music and wherever you stream your podcasts.

Subscribe to the Xtalks Life Science Podcast to never miss a new episode.